Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-63198

Flaherty, K T; Robert, C; Hersey, P; Nathan, P; Garbe, C; Milhem, M; Demidov, L V; Hassel, J C; Rutkowski, P; Mohr, P; Dummer, R; Trefzer, U; Larkin, J; Utikal, J; Dreno, B; Casey, M; Sherman, L J; Wu, F S; Schadendorf, D (2012). Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group. New England Journal of Medicine, 367(2):107-114.

[img]Published Version
PDF - Registered users only
337kB

View at publisher

Abstract

Background
Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population.
Methods
In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio. Patients received trametinib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 weeks. Patients in the chemotherapy group who had disease progression were permitted to cross over to receive trametinib. Progression-free survival was the primary end point, and overall survival was a secondary end point.
Results
Median progression-free survival was 4.8 months in the trametinib group and 1.5 months in the chemotherapy group (hazard ratio for disease progression or death in the trametinib group, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001). At 6 months, the rate of overall survival was 81% in the trametinib group and 67% in the chemotherapy group despite crossover (hazard ratio for death, 0.54;95% CI, 0.32 to 0.92; P = 0.01). Rash, diarrhea, and peripheral edema were the most common toxic effects in the trametinib group and were managed with dose interruption and dose reduction; asymptomatic and reversible reduction in the cardiac ejection fraction and ocular toxic effects occurred infrequently. Secondary skin neoplasms were not observed.
Conclusions
Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation. (Funded by GlaxoSmithKline; METRIC ClinicalTrials
.gov number, NCT01245062.)

Citations

339 citations in Web of Science®
384 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 20 Jun 2012
0 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
DDC:610 Medicine & health
Date:20 June 2012
Deposited On:20 Jun 2012 14:44
Last Modified:29 Nov 2013 15:54
Publisher:Massachusetts Medical Society
ISSN:0028-4793
Publisher DOI:10.1056/nejmoa1203421
PubMed ID:22663011

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page